Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse (TIPA)

I

Institut de Cancérologie de la Loire

Status

Unknown

Conditions

Breast Neoplasms

Treatments

Other: Advanced Practice Nurse consultation

Study type

Interventional

Funder types

Other

Identifiers

NCT02686918
2016-01

Details and patient eligibility

About

The main of this study is to assess the feasibility of a patients follow-up visit receiving trastuzumab subcutaneous by Advanced Practice Nurse.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient care at the Cancer Institute Lucien Neuwirth
  • Patient aged over 18 years
  • Patient with breast cancer overexpressing HER2 adjuvant
  • Patient having finished their chemotherapy treatment with IV followed the oncologist day hospital
  • Patient under Trastzumab subcutaneously
  • Patient affiliated or entitled to a social security scheme (mandatory requirement for all studies)

Exclusion criteria

  • Refusal to participate, most patient protected under guardianship.
  • Patient in inability to understand the course of the study
  • Patient with documented history of cognitive or psychiatric disorders.
  • Patients pregnant or lactating
  • Patients under guardianship or curatorship

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

100 participants in 1 patient group

consultation by Advanced Practice Nurse.
Experimental group
Description:
During consultations, patients will be seen successively by Advanced Practice Nurse and referent oncologist.
Treatment:
Other: Advanced Practice Nurse consultation

Trial contacts and locations

0

Loading...

Central trial contact

Mathieu ORIOL, MD; Cécile MIGALA, IPA

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems